Clinical and molecular characteristics of the 70 patients with AML at diagnosis included in the study.

<p>Clinical and molecular characteristics of the 70 patients with AML at diagnosis included in the study.</p

MicroRNA deregulated by copy number variations in 16 myeloid cell lines.

<p>Amp: amplification; Del: deletion.</p

Functional analysis showing that miR-370 regulates <i>NF1</i>.

<p>(A) miRNAs expression analysis by real-time PCR after transfection with pre-miRs-370, −379, −432 and −494. (B) Western blot showing NF1 after transfection with pre-miR-370. (C) Luciferase assay showing changes in luciferase activity after transfection with pre-miR– (negative control) or pre-miR-370 in cells expressing the 3′UTR region of <i>NF1</i> that includes the miR-370 seed region [pRL-NF1(3′UTR)wt]. Transfection with the 3′UTR region of <i>NF1</i> including a mutated seed region for miR-370 was used as control.</p

Western blot analysis of NF1 in 14 samples of patients with AML at diagnosis.

<p>Data about NF1 status and expression of miR-370 are shown. N: normal control; P: patient sample.</p

Effects of miR-370 on AML cell proliferation.

<p>(A) <i>NF1</i> expression after transfection with pre-miR-370 and anti-miR-370 in TF-1 cells. (B) Cell growth of TF1 cells after transfection with pre-miR-370, anti-miR-370 or miR-Control. Bars represent the mean ± SD of three independent experiments. *<i>P</i><0.05 determined using t-student test. (C) Colony forming ability of TF-1 cells transfected with miR-Control, pre-miR-370 or anti-miR-370. Bars represent the mean ± SD, experiments were done in triplicate. *<i>P</i><0.05 determined using t-student test.</p